EVH icon

Evolent Health

8.62 USD
-0.40
4.43%
At close Updated Sep 15, 4:00 PM EDT
Pre-market
After hours
8.63
+0.01
0.12%
1 day
-4.43%
5 days
-12.22%
1 month
-7.31%
3 months
5.38%
6 months
-13.71%
Year to date
-24.98%
1 year
-71.64%
5 years
-32.76%
10 years
-57.83%
 

About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Employees: 4,500

0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

40% more call options, than puts

Call options by funds: $3.55M | Put options by funds: $2.53M

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

20% more capital invested

Capital invested by funds: $1.18B [Q1] → $1.42B (+$233M) [Q2]

16% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 70

0.06% less ownership

Funds ownership: 107.26% [Q1] → 107.2% (-0.06%) [Q2]

5% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 40

3% less funds holding

Funds holding: 223 [Q1] → 217 (-6) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$13
51% upside
Avg. target
$16.6
93% upside
High target
$20
132% upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Richard Close
$16
Buy
Maintained
9 Sep 2025
BTIG
David Larsen
$20
Buy
Reiterated
9 Sep 2025
Piper Sandler
Jessica Tassan
$18
Overweight
Maintained
28 Aug 2025
Truist Securities
Jailendra Singh
$16
Buy
Maintained
17 Jul 2025
JMP Securities
Constantine Davides
$13
Market Outperform
Reiterated
20 Jun 2025

Financial journalist opinion

Based on 3 articles about EVH published over the past 30 days

Positive
Seeking Alpha
25 days ago
Evolent's Soft Q2 Results: Why I'm Holding Anyway
Evolent's revenue dip in Q1 was structural, not demand-driven, and Q2 shows stabilization; I expect growth to resume in the second half of 2025. New specialty contracts, incremental member growth, and key leadership appointments should drive recovery and enhance clinical and financial credibility. The oversubscribed convertible notes offering signals investor confidence, strengthens liquidity, and supports shareholder value through buybacks and reduced refinancing risk.
Evolent's Soft Q2 Results: Why I'm Holding Anyway
Neutral
PRNewsWire
28 days ago
Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
WASHINGTON , Aug. 19, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced the pricing of $145.0 million aggregate principal amount of 4.50% convertible senior notes due 2031. The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Neutral
PRNewsWire
28 days ago
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
WASHINGTON , Aug. 18, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced that it intends to offer $140.0 million aggregate principal amount of convertible senior notes due 2031, subject to market and other conditions. Evolent also expects to grant the initial purchasers in the proposed offering an option to purchase up to an additional $20.0 million aggregate principal amount of notes.
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Neutral
Seeking Alpha
1 month ago
Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants John Paul Johnson - Chief Financial Officer Seth Barrie Blackley - Co-Founder, CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division Eduardo Enrique Ron - Truist Securities, Inc., Research Division Jared Phillip Haase - William Blair & Company L.L.C.
Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Evolent Health (EVH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Evolent Health (EVH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Negative
Zacks Investment Research
1 month ago
Evolent Health (EVH) Reports Q2 Loss, Misses Revenue Estimates
Evolent Health (EVH) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of $0.09. This compares to earnings of $0.3 per share a year ago.
Evolent Health (EVH) Reports Q2 Loss, Misses Revenue Estimates
Neutral
The Motley Fool
1 month ago
EVH Earnings Drop 31%
EVH Earnings Drop 31%
EVH Earnings Drop 31%
Neutral
PRNewsWire
1 month ago
Evolent Announces Second Quarter 2025 Results
WASHINGTON , Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year.
Evolent Announces Second Quarter 2025 Results
Negative
Zacks Investment Research
1 month ago
Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline
Neutral
PRNewsWire
2 months ago
Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Company to Participate in Upcoming Conferences WASHINGTON , July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Charts implemented using Lightweight Charts™